If you liked this article you might like

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
Alexion Rises More Than 5% After Beating Consensus
Acorda Shares Fall 5% in an Earnings Miss
Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year